Opendata, web and dolomites

RESCUER SIGNED

RESISTANCE UNDER COMBINATORIAL TREATMENT IN ER+ AND ER- BREAST CANCER.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESCUER project word cloud

Explore the words cloud of the RESCUER project. It provides you a very rough idea of what is the project "RESCUER" about.

administering    personalized    everyone    frameworks    exploring    combinations    thin    tested    tumor    silico    solid    therapy    vs    effectiveness    classified    gather    physiological    women    models    sub    actually    computational    overreaching    predict    benefit    model    individual    worldwide    resistance    computer    ex    animal    optimization    vivo    arbitrary    treatment    tried    framework    few    molecular    bc    combinatorial    breast    mechanisms    drug    clinical    subtypes    despite    biological    ongoing    responders    cancer    discover    multidimensional    patient    death    degree    curative    longitudinal    ethical    cellular    combination    drugs    approved    algorithms    first    patients    newly    efficient    trials    endowed    aspects    samples    alternative    organ    data    indication    network    therapies    integrate    strata    omic    omics    heterogeneity    combine    xenograft    purpose    ethics    stratification    probability    signatures   

Project "RESCUER" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITETET I OSLO 

Organization address
address: PROBLEMVEIEN 5-7
city: OSLO
postcode: 313
website: www.uio.no

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 6˙283˙250 €
 EC max contribution 6˙000˙000 € (95%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITETET I OSLO NO (OSLO) coordinator 933˙543.00
2    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 946˙443.00
3    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 935˙625.00
4    UNIVERSITAT DE BARCELONA ES (BARCELONA) participant 466˙337.00
5    VIB BE (ZWIJNAARDE - GENT) participant 464˙375.00
6    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 424˙781.00
7    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 400˙000.00
8    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 389˙012.00
9    INTERDISCIPLINARY CENTER (IDC) HERZLIYA IL (HERZLIYA) participant 371˙875.00
10    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 273˙000.00
11    UNIVERSITATSKLINIKUM ERLANGEN DE (ERLANGEN) participant 245˙712.00
12    INSTITUT FUR FRAUENGESUNDHEIT GMBH DE (ERLANGEN) participant 141˙293.00
13    RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY US (NEW BRUNSWICK) participant 8˙000.00
14    NANTOMICS LLC US (DOVER) participant 0.00
15    NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU NO (TRONDHEIM) participant 0.00

Map

 Project objective

Breast Cancer (BC) is the first cause of cancer-related death in women worldwide. Breast cancer is classified into well-recognized molecular subtypes. Despite solid pre-clinical evidence, only some patients benefit from administering drug combinations, an indication that patient and tumor heterogeneity is still present in the current stratification. Out of the numerous possible combinations of approved drugs, only a few have been actually tried, and the choice of tested combinations has been to some degree arbitrary. This proposal seeks to develop new approaches and identify mechanisms of treatment resistance at systems level, exploring how the effectiveness of specific targeted therapies applied in different clinical trials is affected by patient- and tumor-specific conditions. For this purpose, the project will gather and integrate longitudinal multidimensional data from ongoing clinical trials and newly generated --omics using systems approaches, which combine sub-cellular/cellular and/or organ level in-silico models and network analysis to build computational frameworks able to discover molecular signatures of resistance and predict patient response to combinatorial therapies. We aim to identify the physiological characteristics of non-responders vs. responders from existing and newly generated multi-omic data and biological samples from in-vivo and ex-vivo clinical studies of specific subtypes of BC patients treated with combination therapy. This new knowledge will be used to investigate the curative potential of new personalized drugs combinations. The overreaching goal is to develop computer “xenograft model” as a cost-efficient and better alternative in terms of ethics, availability to everyone, and animal use. The framework will include optimization algorithms to identify combinations of approved drugs with a high probability to work on individual or thin strata of patients. The project is endowed with a “legal” framework addressing ethical aspects

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESCUER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESCUER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More  

ENDpoiNTs (2019)

Novel Testing Strategies for Endocrine Disruptors in the Context of Developmental NeuroToxicity

Read More  

ESPACE (2020)

Human Cell Atlas of the Pancreas

Read More